News – V-Bio Ventures

Newsv-bio-ventures2020-05-07T09:31:51+02:00

Subscribe to our newsletter

V-Bio News

Biodol Therapeutics receives €4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

Published on: August-31, 2020

V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19

Published on: July-28, 2020

V-Bio Ventures invests in RootWave in a EUR 6.5 m Series A financing to develop and market electrical weed killing solutions

Published on: December-16, 2019

V-Bio Ventures invests in Augustine Therapeutics, a VIB and KU Leuven spin-off to fight neuromuscular diseases

Published on: December-16, 2019

V-Bio Ventures leads AgomAb Therapeutics’ Euros 21m Series A Financing

Published on: April-3, 2019

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Published on: Nov-15, 2018

Portfolio News

Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets Copy

Published on: June 4, 2020

Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets

Published on: March 5, 2020

Camel-IDS appoints Ruggero Della Bitta MD, PhD, as Chief Medical Officer

Published on: Okt-8, 2019

Camel-IDS appoints Thomas Ramdahl as Independent Director

Published on: May-17, 2019

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator

Published on: May-8, 2019

Confo Therapeutics raises €30 million in Series A financing

Published on: May-7, 2019

Newsletter